Testing dapagliflozin to prevent GVHD after stem cell transplant
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests whether adding dapagliflozin (a diabetes medication) to standard care can help prevent graft-versus-host disease after a stem cell transplant for blood cancer. It may be an option for adults who are about to receive a transplant from a half-matched or unrelated donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a blood cancer that needs a stem cell transplant from a half-matched or unrelated donor.
- You are willing to receive strong chemotherapy before transplant and take cyclosporine and methotrexate to prevent graft-versus-host disease.
- You are able to get up and do daily activities (ECOG score 0-3).
- You have not had a prior stem cell transplant or CAR T-cell therapy.
- You do not have type 1 diabetes or a history of ketoacidosis, and you do not get frequent urinary tract infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of medications given before and after a stem cell transplant from a family member to prevent graft-versus-host disease (GVHD)—a condition where the new cells attack your body. The study includes a newer drug called ivarmacitinib that may help reduce this serious side effect.
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
This study tests whether a diabetes drug called dapagliflozin (Farxiga) can help protect your kidney function and heart health after a kidney transplant. It's for people who have had a transplant for at least a year and have diabetes or post-transplant diabetes.
This trial tests whether taking dapagliflozin (a drug often used for diabetes and heart health) can help improve kidney structure and blood flow in people who received a kidney transplant at least 9 months ago. It may benefit those whose kidney function is stable, regardless of whether they have diabetes.
This study tests whether dapagliflozin (a medicine already approved for other heart conditions) can help protect kidney and heart function in people with very advanced heart failure who are waiting for a heart transplant. If you qualify, you'll help researchers learn if this drug offers extra benefits beyond standard care.
This trial tests a new way to prevent graft-versus-host disease (GVHD) after a stem cell transplant in people who have already received PD-1 immunotherapy. The goal is to make the transplant safer and more effective.
Hear when a new Graft-versus-host Disease (GVHD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.